ClinicalTrials.gg
CompletedNCT05510908Updated Nov 5, 2026Results posted

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

An observational study in HIV-Associated Malignant Neoplasm, HIV Infections and Cancer, sponsored by AIDS Malignancy Consortium. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by AIDS Malignancy Consortium · Observational

How we know

Updated Nov 5, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
460
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in HIV Infections by AIDS Malignancy Consortium — 3 open to participants now, 4 under way, none of them phase 3. HIV Infections · AIDS Malignancy Consortium.

Enrollment
Largest of 13
460 · median 82
Started
2023
with 2 others
Observational
13 of 29
1 open now
Registered
27th of 29
by date

Among the 29 studies in HIV Infections by AIDS Malignancy Consortium, this one has the largest enrollment of the 13 observational ones that give a count, is one of 3 that started in 2023, is one of 13 observational ones, and was the 27th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

3 of the 29 studies in HIV Infections by AIDS Malignancy Consortium are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in HIV Infections by AIDS Malignancy Consortium, or all of them as a file.
02

Study summary

This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.

Read the detailed description

Primary Objective: To estimate the number of cancers in people with HIV (PWH) who present for care at domestic AMC sites

Secondary Objectives: To characterize participants that are eligible but not enrolled onto AMC clinical trials to understand site-specific and trial-specific accrual barriers

Exploratory Objectives: 1. To standardize and expand the quantity and quality of sociodemographic and cancer diagnostic and treatment characteristics collected for PWH receiving care at domestic AMC sites. 2. To describe cancer patient health-related QOL for PWH at domestic AMC sites using validated tools: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30] and Supportive Care Needs Survey Short Form 34 [SCNS-SF34]

Outline: Participants identified via screening of electronic medical records or institutional databases. All eligible participants attend one visit for the collection of broad demographic and clinical data. Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit. Data collection at study visits will occur via survey procedures and/or medical record review.

03

Conditions studied

  • HIV-Associated Malignant Neoplasm
  • HIV Infections
  • Cancer
  • AIDS Related Lymphoma
  • AIDS-related Kaposi Sarcoma
  • AIDS-Related Malignancy
  • Anal Cancer
  • HPV-Related Malignancy

Keywords

  • HIV-Related Cancer
  • AIDS
  • AIDS-related malignancy
  • anal cancer
  • lymphoma
  • kaposi sarcoma
  • cervical cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with a dual diagnosis of both cancer (current or diagnosed within 5 years) and underlying HIV infection, who present for care at AMC domestic sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant can understand and is willing to sign a written document.
  • positive. Documentation of HIV-1 infection by means of any one of the following:

    • Documentation of an HIV diagnosis in the medical record by a licensed health care provider;
    • Documentation of receipt of antiretroviral therapy (ART) (i.e., at least two different medications that do not constitute a prescription for pre-exposure prophylaxis [PrEP]) by a licensed health care provider. Documentation may be a record of an ART prescription in the medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name;
    • HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating >1000 RNA copies/mL;
    • Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.

Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).

WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay, or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), a Western blot, or a plasma HIV-1 RNA viral load.

  • Patient was diagnosed with or treated for cancer within the last 5 years. Participants will qualify under one of three categories:

    • New, primary or recurrent diagnosis -Considering or currently receiving cancer treatment
    • or locally advanced cancer - This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
    • Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
  • Age ≥ 18 years.
  • Participant presents to an AMC domestic clinical trial site for either clinical care or research.

Exclusion criteria

Exclusion Criteria:

  • Participants who do not fulfill the criteria as listed above are ineligible.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
460 participants (actual)
Patient registry
No

Groups and cohorts

  • New, primary or recurrent disease

    Considering or currently receiving cancer treatment

    Other: Non-Interventional · Other: Non-Interventional Follow-up

  • Metastic or locally advanced cancer

    This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.

    Other: Non-Interventional · Other: Non-Interventional Follow-up

  • Prior cancer

    Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

  • OtherNon-Interventional Follow-up

    Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

06

What researchers measure

Primary outcomes

  1. Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites

    For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies

    Time frame: Enrollment

Secondary outcomes

  1. Percentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled

    This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.

    Time frame: Baseline

Other outcomes

  1. Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

    The distribution of participant cancer diagnosis variable will be summarized.

    Time frame: Baseline

  2. Describe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

    The distribution of participant gender variable will be summarized.

    Time frame: Baseline

  3. Describe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

    The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).

    Time frame: Baseline and 12 weeks

  4. Describe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

    The distribution of participant cancer treatment at enrollment will be summarized.

    Time frame: Baseline

  5. Planned Cancer Therapy for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment

    The frequency of planned cancer treatment regimens (at baseline) successfully initiated will be summarized.

    Time frame: 12 weeks

  6. Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

    EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.

    Time frame: Baseline

  7. Describe the Supportive Care Needs of Cancer Patients With HIV at Domestic AMC Sites Using Supportive Care Needs Survey Short Form 34 [SCNS-SF34]

    Supportive Care Needs Survey Short Form 34 \[SCNS-SF34\] scores will be used to categorize participants based on the degree to which their needs are met. Baseline SCNS-SF34 scores will be compared according to cancer group. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need); with a higher score indicating a higher level of need.

    Time frame: Baseline

  8. Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

    EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.

    Time frame: Baseline and 12 weeks

  9. Change of Needs From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using Supportive Care Needs Short Survey Form 34 [SCNS-SF34]

    Supportive Care Needs Short Survey Form 34 \[SCNS-SF34\] scores will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in scores will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need). Scores are averaged, and transformed to 0-100 scale;, with a higher score indicating a higher level of need.

    Time frame: Baseline and 12 weeks

07

Results

Posted Mar 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Started26833159
Completed26833159
Not completed000

Outcome measures

PrimaryNumber of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites

For each cancer group listed below, the number of new and existing cases per month will be estimated. The distribution of cancer types will be computed as percentages and compared to the cancer type distribution in the HIV/AIDS Cancer Match (HACM) Study: 1. Solid organ tumors associated with human papillomavirus (HPV) infection 2. Solid organ tumors unrelated to HPV 3. Kaposi sarcoma 4. Hematologic malignancies

Time frame:
Enrollment
Reported as:
Count of participants · Participants
Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites
ParticipantsNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Hematologic malignancies43035
Kaposi sarcoma87615
Solid organ tumor associated with HPV infection301032
Solid organ tumors unrelated HPV551355
Other52422
Unknown100
SecondaryPercentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled

This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.

Time frame:
Baseline
Reported as:
Number · percentage of enrolled in AMC studies
Percentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled
percentage of enrolled in AMC studiesNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Percentage of Participants Eligible for AMC Trials Who Are Successfully Enrolled405050
Other pre-specifiedDescribe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

The distribution of participant cancer diagnosis variable will be summarized.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
ParticipantsNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Hematologic malignancy86153
Kaposi Sarcoma85420
Solid Tumors associated with HPV infection30736
Solid Tumors unrelated to HPV602048
Unknown712
Other pre-specifiedDescribe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

The distribution of participant gender variable will be summarized.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Describe the Gender Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
ParticipantsNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Female37331
Male22130125
Transgender402
Refused300
Unknown301
Other pre-specifiedDescribe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

The distribution of participant characteristics will be summarized. Continuous variables \[e.g. age, height, weight\] will be summarized as mean (std) if they are normally distributed, otherwise they will be summarized as median (IQR). Categorical variables \[e.g. tobacco use, ART medications, comorbidities\] will be summarized as frequency (%).

Time frame:
Baseline and 12 weeks
Reported as:
Count of participants · Participants
Describe the Age Distribution of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
ParticipantsNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Age: <50 years104935
Age:50-59 years63946
Age:60-69 years771364
Age: >=70 years24214
Other pre-specifiedDescribe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.

The distribution of participant cancer treatment at enrollment will be summarized.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Describe the Treatment Characteristics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
ParticipantsNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
No Cancer treatment at enrollment102101
Cancer Treatment at enrollment (Chemotherapy)131170
Cancer Treatment at enrollment (Non-chemotherapy)3350
Unknown21158
Other pre-specifiedPlanned Cancer Therapy for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment

The frequency of planned cancer treatment regimens (at baseline) successfully initiated will be summarized.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Planned Cancer Therapy for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment
ParticipantsNew, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Planned additional therapy95140
No additional therapy171181
Unknown/missing21158
Other pre-specifiedDescribe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

EORTC QLQ-C30 subscale and overall scores will be used to describe participant symptom and health-related quality of life burden. Baseline EORTC QLQ-C30 scores will be compared according to cancer group. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and single items assessing additional symptoms and perceived financial impact of the disease. Most questions use a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions use a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.

Time frame:
Baseline
Reported as:
Median · score on a scale between 0 and 100
Describe the Health-related QOL of Cancer Patients With HIV at Domestic AMC Sites Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
score on a scale between 0 and 100New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Global Health75 (7.14 to 92.86)60.7 (7.14 to 92.86)71.4 (7.14 to 92.85)
Functional Scale58.3 (5 to 76.67)58.3 (13.3 to 76.67)65 (21.67 to 76.67)
Symptom Scale44.2 (23.1 to 92.3)43.3 (26.9 to 90.38)34.6 (23.1 to 86.53)
Other pre-specifiedDescribe the Supportive Care Needs of Cancer Patients With HIV at Domestic AMC Sites Using Supportive Care Needs Survey Short Form 34 [SCNS-SF34]

Supportive Care Needs Survey Short Form 34 \[SCNS-SF34\] scores will be used to categorize participants based on the degree to which their needs are met. Baseline SCNS-SF34 scores will be compared according to cancer group. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need); with a higher score indicating a higher level of need.

Time frame:
Baseline
Reported as:
Mean · score on a scale between 0 and 100
Describe the Supportive Care Needs of Cancer Patients With HIV at Domestic AMC Sites Using Supportive Care Needs Survey Short Form 34 [SCNS-SF34]
score on a scale between 0 and 100New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Physical and daily living needs51.6 ± 22.255.7 ± 25.745.3 ± 23.4
Psychological needs50.4 ± 21.554.9 ± 24.343 ± 18.7
Sexual needs40.8 ± 22.441.7 ± 17.735.5 ± 19.6
Care and support needs39.7 ± 17.441.8 ± 17.136.6 ± 15.5
Health system and information needs43.5 ± 18.644.9 ± 15.638.4 ± 15.2
Other pre-specifiedChange of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]

EORTC QLQ-C30 will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in QOL will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The EORTC QLQ-C30 is a 30-item core cancer specific questionnaire measuring QOL in cancer patients. It incorporates five functional scales (physical, role,cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms and perceived financial impact of the disease. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=higher response level.

Time frame:
Baseline and 12 weeks
Reported as:
Median · score on a scale between -100 and 100
Change of Quality of Life at 12 Weeks From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30]
score on a scale between -100 and 100New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Global Health Scale0 (-57.1 to 85.7)0 (-42.9 to 28.6)0 (-14.3 to 14.3)
Functional Scale1.7 (-21.7 to 35)-2.5 (-15 to 38.3)0 (-1.7 to 3.3)
Symptom Scale-1.9 (-40.4 to 28.8)0 (-26.9 to 13.5)0 (0 to 3.8)
Other pre-specifiedChange of Needs From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using Supportive Care Needs Short Survey Form 34 [SCNS-SF34]

Supportive Care Needs Short Survey Form 34 \[SCNS-SF34\] scores will be summarized, both overall and at the \~12-week follow-up, according to participant characteristics and cancer groups. Overall change in scores will be compared with paired tests and change according to groups will be compared using t-tests, ANOVA, or nonparametric tests. The SCNS-SF34 is a 34-item questionnaire measuring the supportive care need and level of need for people diagnosed with cancer in the last month. It incorporates the underlying domains: physical and daily living, psychological, sexuality and health system, information and patient support. All the questions use 5-point scale (1 'Not applicable' to 5 'High need). Scores are averaged, and transformed to 0-100 scale;, with a higher score indicating a higher level of need.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · score on a scale between -100 and 100
Change of Needs From Baseline for Cancer Patients With HIV Initiating Therapy or Currently Under Treatment Using Supportive Care Needs Short Survey Form 34 [SCNS-SF34]
score on a scale between -100 and 100New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior Cancer
Physical and daily living needs-1.75 ± 19.19.5 ± 20.8-0.8 ± 1.8
Psychological needs-3.17 ± 16.50.3 ± 29.70.3 ± 1.4
Sexual needs-3.2 ± 19.5-4.2 ± 15.1-1.1 ± 2.7
Care and support needs-2.7 ± 14.09.3 ± 19.80 ± 0
Health system and information needs-1.3 ± 17.41.8 ± 12.4-0.3 ± 0.7

Adverse events

Collected over This study is observational study. Adverse events are not collected.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
New, Primary or Recurrent Disease———
Metastic or Locally Advanced Cancer———
Prior Cancer———

Baseline characteristics

Age, Continuous
Age, Continuous(years)New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior CancerTotal
Median55 (20 to 83)59 (27 to 71)59 (23 to 83)57 (20 to 83)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior CancerTotal
Female3733171
Male22130125376
Transgender4026
Not reported/Unknown6017
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior CancerTotal
Hispanic or Latino62445111
Not Hispanic or Latino19929107335
Unknown or Not Reported70714
Race (NIH/OMB)
Race (NIH/OMB)(Participants)New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior CancerTotal
American Indian or Alaska Native2002
Asian3025
Native Hawaiian or Other Pacific Islander3003
Black or African American1011761179
White1251570210
More than one race2002
Unknown or Not Reported3212659
Education
Education(Participants)New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior CancerTotal
Never attended school2013
High school graduate or below57748112
College degree or equivalent771147135
Unknown/not reported1321563210
Smoking history
Smoking history(Participants)New, Primary or Recurrent DiseaseMetastic or Locally Advanced CancerPrior CancerTotal
Current use54103195
Quit/former use1111157179
Never used1021270184
Unknown1012
08

Study locations

16 sites
  • Moores UCSD Cancer Center
    La Jolla, California 92903, United States
  • George Washington University Cancer Center
    Washington D.C., District of Columbia 20037, United States
  • University of Miami Miller School of Medicine-Sylvester Cancer Center
    Miami, Florida 33136, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Weill Cornell Medicine - Cornell Clinical Trials Unit
    New York, New York 10010, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Abramson Cancer Center at Pennsylvania Hospital
    Philadelphia, Pennsylvania 19106, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute - University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Puerto Rico
    San Juan, 00921, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Feb 2025, 19 months.

Results were first posted in Mar 2026, 1 year after primary completion.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 19 months is below that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 22, 2022
StartActual
Jul 25, 2023
Primary completionActual
Feb 28, 2025
CompletionActual
Jun 2, 2025
Results first posted
Mar 25, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 5, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedProportionPercentage of Participants Eligible for AMC Trials Who Are Successfully EnrolledTime frame: Baseline
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Posted results revised
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedProportionPercentage of Participants Eligible for AMC Trials Who Are Successfully EnrolledTime frame: Baseline
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05510908
Lead sponsor
AIDS Malignancy Consortium
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Jul 25, 2023
Primary completion
Feb 28, 2025
Completion
Jun 2, 2025
Results posted
Mar 25, 2026
Last update
Nov 5, 2026

Study contacts

Anna E Coghill, PhD, MPH
study chair · AIDS Malignancy Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion